% | $
Quotes you view appear here for quick access.

Protalix BioTherapeutics, Inc. (PLX) Message Board

  • dinepat203 dinepat203 Feb 5, 2013 1:22 PM Flag

    Isreal News paper also reported about AMARIN

    At this stage, Amarin must decide whether to expand and take on Vascepa's marketing and sales operations or to outsource these operations.

    Meanwhile, Amarin's board is pushing for the sale of the company, and it is likely that the buyer will have to pay Amarin shareholders more than $2.2 billion.

    Amarin also has several pipeline products for the treatment of central nerve system disorders, which is also Teva's leading innovative field of activity (including MS treatment Copaxone, and Provigil, Nuvigil and Azilect).

0.58+0.010(+1.74%)Sep 29 4:00 PMEDT